Drug intelligence / Profile preview

enzolvantinib

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

Enzolvantinib appears to be an investigational **small-molecule tyrosine kinase inhibitor** that was in early clinical development at Turning Point Therapeutics. Publicly accessible evidence confirms the asset name and its association with Turning Point Therapeutics, but the specific target profile, intended indication, formulation details, and clinical status are not clearly described in reliable primary sources currently available. Because the publicly retrievable information is extremely limited, the pharmacology and development context for this asset remain insufficiently characterized from accessible sources.

Targets

MET (Mesenchymal-epithelial transition factor receptor)CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on enzolvantinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enzolvantinib.

Explore the full profile